Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 8/20 | 0.52 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.47 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.47 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.47 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195431 | 0.89 | L3MBTL1 (0.63) | L3MBTL1HTR6ALDH1A1KDM4EPKM | |
| SCHEMBL7186615 | 0.88 | LMNA (0.63) | L3MBTL1HTR6ALDH1A1PKMLMNA | |
| SCHEMBL4363463 | 0.85 | L3MBTL1 (0.73) | L3MBTL1HTR6ALDH1A1KDM4EGAA | |
| SCHEMBL29480329 | 0.81 | HTR6 (0.66) | HTR6ALDH1A1KDM4EPKMGAA | |
| SCHEMBL1162839 | 0.81 | HTR6 (0.66) | HTR6ALDH1A1KDM4EPKMGAA | |
| SCHEMBL30513963 | 0.81 | ALDH1A1 (0.54) | HTR6ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL2487383 | 0.81 | ALDH1A1 (0.54) | HTR6ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL4400959 | 0.81 | HTR6 (0.56) | L3MBTL1HTR6ABCC9ABCC8KCNJ11 | |
| SCHEMBL7181927 | 0.79 | L3MBTL1 (0.56) | L3MBTL1HTR6ALDH1A1KDM4EPKM | |
| SCHEMBL7182100 | 0.79 | L3MBTL1 (0.56) | L3MBTL1HTR6ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5684198-A | N-ARYL-2-HYDROXYPROPANAMIDES | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5567735-A | CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5565477-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5565465-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| EP-0524781-B1 | Therapeutic amides | ZENECA LTD (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | L3MBTL1 990/4885HTR6 4140/4885ABCC9 1447/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | L3MBTL1 990/4885HTR6 4140/4885ABCC9 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.